Isotretinoin

Retinoid Vitamin A derivative

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 0.5-2 mg/kg q12h or q24h Duration: 8-16 weeks (may require maintenance)
Notes: Start at low end and titrate based on response and adverse effects. Administer with food.
Cat PO 0.5-1 mg/kg q24h Duration: 8-12 weeks
Notes: Use cautiously; cats are sensitive to adverse effects. Monitor for anorexia and hepatic toxicity.
Horse PO 1-2 mg/kg q24h Duration: 4-8 weeks
Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications
  • Treatment of keratinization disorders and sebaceous gland diseases
Dog (Canine)
  • Sebaceous adenitis
  • Idiopathic acne
  • Comedone syndrome
  • Ichthyosis
  • Nasal parakeratosis
  • Miscellaneous keratinization disorders
Cat (Feline)
  • Feline acne (severe, refractory)
  • Idiopathic facial dermatitis
  • Sebaceous adenitis (rare)
Horse (Equine)
  • Equine acne
  • Hyperkeratosis
  • Dermatophilosis (adjunct)
Cattle (Bovine)
  • No established indications
Small Ruminants (Sheep / Goat)
  • No established indications
Rabbit & Small Mammals
  • No established indications
Avian & Poultry
  • No established indications
Exotic & Other Species
  • No established indications

Pharmacology & Mechanism of Action

Drug Class: Retinoid | Pharmacological Group: Vitamin A derivative

Mechanism of Action: Isotretinoin (13-cis-retinoic acid) is a synthetic retinoid that binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription. It reduces sebum production by inhibiting sebocyte proliferation and inducing apoptosis, decreases sebaceous gland size, and normalizes follicular keratinization. It also has anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and pro-inflammatory cytokines.

Pharmacodynamics: Isotretinoin decreases sebum excretion rate by up to 90% in a dose-dependent manner. It reduces the size and activity of sebaceous glands, leading to decreased comedone formation. It also alters the skin microbiome and reduces inflammation. Clinical improvement in acne and sebaceous adenitis is typically seen within 4-8 weeks, with maximal effect at 12-16 weeks.

⚡ Pharmacokinetics Summary

Absorption: Isotretinoin is lipophilic and well absorbed orally, especially when given with a high-fat meal. Peak plasma concentrations occur within 2-4 hours. In dogs, oral bioavailability is approximately 25% due to first-pass metabolism.
Distribution: Extensively bound to plasma proteins (99.9%), mainly albumin. It distributes widely into tissues, including skin, sebaceous glands, and adipose tissue. It crosses the blood-brain barrier and placenta.
Metabolism: Metabolized in the liver primarily by CYP450 enzymes (CYP3A4, CYP2C8, CYP2C9) to active metabolites such as 4-oxo-isotretinoin and tretinoin. Enterohepatic recirculation occurs.
Excretion: Excreted in bile and urine as metabolites. The terminal half-life is approximately 21 hours in dogs and 29 hours in humans, but may be longer in some species.
Half-Life: Dogs: ~21 hours; Cats: ~24 hours (estimated); Humans: ~21 hours
Bioavailability: Oral: ~25% in dogs (increased with food)
Protein Binding: >99.9%

Available Formulations & Strengths

Oral Capsule 10 mg, 20 mg, 30 mg, 40 mg (PO)
Oral Gel 10 mg/g (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Pregnancy or breeding animals (teratogenic)
  • Hypersensitivity to isotretinoin or other retinoids
  • Concurrent use of tetracyclines (increased risk of pseudotumor cerebri)
  • Severe hepatic or renal impairment
  • Hypervitaminosis A
Warnings & Clinical Precautions:
  • Teratogenic: do not use in pregnant or lactating animals; wear gloves when handling capsules.
  • May cause hyperlipidemia; monitor triglycerides and cholesterol.
  • May cause hepatotoxicity; monitor liver enzymes.
  • May cause bone abnormalities in young animals; avoid in growing animals unless necessary.
  • May cause dry eyes and corneal opacities; monitor ocular health.
  • Use with caution in animals with diabetes mellitus or pancreatitis.
  • May cause behavioral changes; monitor for depression or aggression.
  • Do not administer vitamin A supplements concurrently.

Adverse Effects & Reactions

Common:

  • Anorexia
  • Vomiting
  • Diarrhea
  • Lethargy
  • Dry skin and mucous membranes
  • Pruritus
  • Increased thirst and urination

Serious / Severe:

  • Hyperlipidemia
  • Hepatotoxicity
  • Pancreatitis
  • Pseudotumor cerebri (with tetracyclines)
  • Bone abnormalities (premature epiphyseal closure)
  • Teratogenicity

Rare:

  • Corneal opacities
  • Cataracts
  • Thrombocytopenia
  • Anemia
  • Seizures

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Tetracyclines (e.g., doxycycline, minocycline) Increased risk of pseudotumor cerebri (benign intracranial hypertension) High
Vitamin A or other retinoids Additive toxicity (hypervitaminosis A) High
Corticosteroids Increased risk of hyperlipidemia and immunosuppression Moderate
Phenytoin Decreased phenytoin metabolism Moderate
Anticoagulants (e.g., warfarin) Potential altered anticoagulant effect Mild

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe vomiting
  • Diarrhea
  • Anorexia
  • Lethargy
  • Ataxia
  • Seizures
  • Hepatotoxicity
  • Hyperlipidemia
  • Bone pain

Emergency Treatment Protocol: Induce emesis if recent ingestion and animal is conscious. Administer activated charcoal. Provide supportive care including IV fluids, antiemetics, and monitoring of liver enzymes and lipid profile. No specific antidote. Treatment is symptomatic and supportive.

Food Animal Withdrawal Times

Not approved for food animals; do not use in animals intended for food production.

Storage, Handling & Regulatory Information

Storage Temperature: Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F)

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in original container.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; used extra-label in companion animals.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited. In companion animals, use is permitted under veterinary discretion. Follow AMDUCA guidelines for extra-label use in non-food animals.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Isotretinoin is a potent retinoid used primarily in dogs for sebaceous adenitis and severe acne. It is highly effective but has significant adverse effects, particularly teratogenicity and hyperlipidemia. Baseline and periodic monitoring of serum triglycerides, cholesterol, and liver enzymes is recommended. Use with caution in breeding animals and young animals. Response may take several weeks; owners should be counseled on the importance of compliance and potential side effects. Due to cost and availability, alternatives like vitamin A or synthetic retinoids may be considered.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)